H Irene Su1, Meghan W Connell2, Lyudmila A Bazhenova3. 1. Department of Reproductive Medicine, University of California, San Diego, La Jolla, California; Moores Cancer Center, University of California, San Diego, La Jolla, California. Electronic address: hisu@ucsd.edu. 2. Reproductive Partners Medical Group - San Diego, La Jolla, California. 3. Moores Cancer Center, University of California, San Diego, La Jolla, California.
Abstract
OBJECTIVE: To describe a clinical approach to and outcomes of IVF in reproductive-aged cancer survivors receiving targeted cancer therapies. DESIGN: Case report. SETTING: Not applicable. PATIENT(S): The first case is of a female patient with metastatic lung cancer receiving long-term crizotinib, an anaplastic lymphoma kinase inhibitor. The second case is of a female patient with metastatic colon cancer receiving long-term denosumab, a RANKL antibody. Both patients presented desiring fertility. INTERVENTION(S): In vitro fertilization. MAIN OUTCOME MEASURE(S): Live birth and embryo banking. RESULT(S): The potential impact of targeted therapy on oocytes and pregnancy was investigated via literature review and pharmaceutical company inquiries. After oncologic, fertility, and psychological counseling, both survivors underwent ovarian stimulation, IVF, and preimplantation genetic screening. One couple achieved live births of dizygotic twins via gestational surrogacy. The second couple froze one euploid blastocyst for future fertility. Both survivors are stable from their cancer standpoints. CONCLUSION(S): Successful fertility treatments are possible in the context of exposure to crizotinib and denosumab.
OBJECTIVE: To describe a clinical approach to and outcomes of IVF in reproductive-aged cancer survivors receiving targeted cancer therapies. DESIGN: Case report. SETTING: Not applicable. PATIENT(S): The first case is of a female patient with metastatic lung cancer receiving long-term crizotinib, an anaplastic lymphoma kinase inhibitor. The second case is of a female patient with metastatic colon cancer receiving long-term denosumab, a RANKL antibody. Both patients presented desiring fertility. INTERVENTION(S): In vitro fertilization. MAIN OUTCOME MEASURE(S): Live birth and embryo banking. RESULT(S): The potential impact of targeted therapy on oocytes and pregnancy was investigated via literature review and pharmaceutical company inquiries. After oncologic, fertility, and psychological counseling, both survivors underwent ovarian stimulation, IVF, and preimplantation genetic screening. One couple achieved live births of dizygotic twins via gestational surrogacy. The second couple froze one euploid blastocyst for future fertility. Both survivors are stable from their cancer standpoints. CONCLUSION(S): Successful fertility treatments are possible in the context of exposure to crizotinib and denosumab.
Authors: Jeanine L Bussiere; Ian Pyrah; Rogely Boyce; Dan Branstetter; Mark Loomis; Dina Andrews-Cleavenger; Cynthia Farman; Glenn Elliott; Gary Chellman Journal: Reprod Toxicol Date: 2013-07-22 Impact factor: 3.143
Authors: A Lipton; K Fizazi; A T Stopeck; D H Henry; M R Smith; N Shore; M Martin; S Vadhan-Raj; J E Brown; G E Richardson; F Saad; D A Yardley; K Zhou; A Balakumaran; A Braun Journal: Eur J Cancer Date: 2015-12-13 Impact factor: 9.162
Authors: Joseph M Letourneau; James F Smith; Erin E Ebbel; Amaranta Craig; Patricia P Katz; Marcelle I Cedars; Mitchell P Rosen Journal: Cancer Date: 2012-03-26 Impact factor: 6.860
Authors: Sara E Barton; Julie S Najita; Elizabeth S Ginsburg; Wendy M Leisenring; Marilyn Stovall; Rita E Weathers; Charles A Sklar; Leslie L Robison; Lisa Diller Journal: Lancet Oncol Date: 2013-07-13 Impact factor: 41.316
Authors: Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245